Differences in PAR-2 activating potential by king crab (Paralithodes camtschaticus), salmon (Salmo salar), and bovine (Bos taurus) trypsin
© Larsen et al.; licensee BioMed Central Ltd. 2013
Received: 21 February 2013
Accepted: 3 July 2013
Published: 20 July 2013
Salmon trypsin is shown to increase secretion of the pro-inflammatory cytokine interleukin (IL)-8 from human airway epithelial cells through activation of PAR-2. Secretion of IL-8 induced by king crab trypsin is observed in a different concentration range compared to salmon trypsin, and seems to be only partially related to PAR-2 activation. This report aim to identify differences in the molecular structure of king crab trypsin (Paralithodes camtschaticus) compared to salmon (Salmo salar) and bovine trypsin (Bos taurus) that might influence the ability to activate protease-activated receptor-2 (PAR-2).
During purification king crab trypsin displayed stronger binding capacity to the anionic column used in fast protein liquid chromatography compared to fish trypsins, and was identified as a slightly bigger molecule. Measurements of enzymatic activity yielded no obvious differences between the trypsins tested. Molecular modelling showed that king crab trypsin has a large area with strong negative electrostatic potential compared to the smaller negative areas in bovine and salmon trypsins. Bovine and salmon trypsins also displayed areas with strong positive electrostatic potential, a feature lacking in the king crab trypsin. Furthermore we have identified 3 divergent positions (Asp196, Arg244, and Tyr247) located near the substrate binding pocket of king crab trypsin that might affect the binding and cleavage of PAR-2.
These preliminary results indicate that electrostatic interactions could be of importance in binding, cleavage and subsequent activation of PAR-2.
KeywordsKing crab trypsin Molecular modelling Protease-activated receptor-2 Electrostatic interaction
Trypsin is a known activator of protease-activated receptor (PAR)-2 [1, 2]. Receptor activation by proteases is achieved by proteolytic cleavage of the N-terminal sequence. This cleavage unmasks a new amino terminus that serves as a tethered ligand that binds to conserved regions in the body of the receptor, resulting in the initiation of signal transduction . Exogenously applied synthetic peptides based on the sequence of the tethered ligand are also capable of activating PARs by directly binding to the body of the receptor. To date, four PARs have been cloned and characterized; PAR-1, PAR-2, PAR-3, and PAR-4. PARs have emerged as important receptors in airway inflammation and allergy, and PARs are expressed in all cell types that participate in the inflammatory response of the lung; epithelial cells, mast cells, macrophages, infiltrated neutrophils and eosinophils, fibroblasts, smooth muscle cells, endothelial cells, lymphocytes, and neurons [4, 5].
Our previous work has confirmed that purified salmon trypsin increase secretion of the pro-inflammatory cytokine interleukin (IL)-8 from human airway epithelial cells through activation of PAR-2 . Secretion of cytokines from the airway epithelium contributes to an inflammation response and can be induced by both endogenous and exogenous proteases . Based on the knowledge that occupational airway symptoms are frequently presented by workers handling different species of fish and crustaceans [7–15], we have tested several types of seafood trypsins in our cell based assays. This in order to investigate possible initiation of signal transduction connected to inflammation processes in human airway epithelial cells [6, 16]. During purification of numerous fish trypsins (Atlantic salmon [Salmo salar], sardine [Sardinops melanostictus], anchovy [Engraulis japonicus], jacopever [Sebastes schlegelii], yellow tail [Seriola quinqueradiata], spotted mackerel [Scomber australasicus] ) and trypsin from the king crab (Paralithodes camtschaticus) by fast protein liquid chromatography (FPLC), we observed that king crab trypsin bound stronger to the anionic column compared to the fish trypsins we purified.
Molecular size, conformation and electrostatic potential will influence on a molecule’s ability to bind and interact with signalling partners. To bind tightly, the ligand must possess a shape and a charge distribution that are complementary to the target receptor [17, 18]. In the molecular complex formed, attractive van der Waals and electrostatic (charge-charge) interactions are made across the binding interface. While the van der Waals interactions are relatively non-specific and small in magnitude, the electrostatic (charge-charge) interactions are highly specific and act over a significantly longer range. A small chemical change as conversion of one amino acid from L- to D- form or substitution of amino acids can inactivate the molecule, as the receptor may fail to bind the altered form or bind it less efficiently. The nature of the interaction between two signalling partners will influence upon downstream signalling pathways following molecular interaction leading to activation and transmission of the molecular signal (full or partial agonists) or inactivation without signal transduction (antagonists) .
We decided to explore the observed divergence between king crab and fish trypsins further. Purified salmon, sardine, bovine and king crab trypsins were evaluated by their ability to hydrolyze a chromogenic substrate (DL-BAPNA) and molecular modelling was executed of salmon, bovine and king crab trypsins for comparison of molecular structure and possibly identification of important amino acids in the trypsin – PAR-2 interaction.
Na-Benzoyl-D,L-arginine 4-nitroanilide hydrochloride (DL-BAPNA) and trypsin from bovine pancreas (T7309) were purchased from Sigma-Aldrich, MO, USA. Purified salmon trypsin was kindly provided by Dr. Nils Peder Willassen and Dr. Ronny Helland (University of Tromsø). King crab trypsin was manufactured by Dr. Galina N. Rudenskaya (Moscow State University), and the sardine trypsin was supplemented by Dr. Hideki Kishimura (Hokkaido University).
The protein concentration was determined with a NanoDrop ND-1000 spectrophotometer (Thermo Scientific) using the Protein A280 determination module.
Fast protein liquid chromatography (FPLC)
All purification steps were carried out at 0-4°C. The freeze dried trypsins prepared according to Rudenskaya et al. , Kislitsyn et al. , and Kishimura et al.  were re-suspended in 25 mM TrisHCl, pH 7.5 and applied to a 1.5 ml benzamidine-sepharose 6B column equilibrated with 25 mM TrisHCl, 10 mM CaCl2, 500 mM NaCl, pH 7.5. Bound trypsin was eluted using 120 mM benzamidine and collected in 1.5 ml fractions. All fractions with enzymatic activity measured by the serine protease assay (DL-BAPNA) were pooled and dialyzed against 25 mM TrisHCl, 10 mM CaCl2, pH 7.5 at 4°C over night using 10K Slide-A-Lyzer dialysis cassettes from Pierce, IL, USA. The following day the benzamidine purified trypsins were applied to a 1 ml Resource Q ion exchange column equilibrated with 25 mM TrisHCl, 10 mM CaCl2, pH 7.5 and the enzymes were eluted with 1 M NaCl using a 7.5% gradient for 10 fractions (total of 5 ml) followed by a linear gradient rising to 100% in 20 fractions (total of 10 ml). Fractions corresponding to the observed peaks were tested for enzymatic activity and pooled before dialysis as described previously.
After purification the trypsins were run on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (4-12% NUPAGE; Invitrogen) and stained with SilverQuestTM Silver Staining Kit (Invitrogen) for verification of their purity.
Protease activity determination
The enzymatic activity of the purified trypsins was determined by a serine protease assay where the hydrolyzation of a chromogenic substrate (DL-BAPNA) was measured spectrophotochemically by the increase in absorbance at 405 nm at room temperature or 37°C for the length of 10 min. The substrate was diluted in substrate buffer (25 mM TrisHCl, 10 mM CaCl2, 2% (v/v) DMSO, pH 8.1) and used at a final concentration of 0.5 mM. The activity was measured in a total volume of 250 μl (10 μl of enzyme and 240 μl of diluted substrate) in clear, 96 well trays with flat bottom (BD Falcon, NJ, USA). The results were expressed as units (U)/ml , and one unit of activity was defined as 1 μmol substrate hydrolyzed per minute using an extinction coefficient of 8800 M-1cm-1. The calculations were made using the following formula: Unit : dA/dt × 1/(ϵ × optical path length × 106) × Vfinal, where dA/dt = rate of absorbance change and ϵ = extinction coefficient.
A homology model of king crab trypsin (Paralithodes camtschaticus; TREMBL accession code: Q8WR10_PARCM) was built by using ICM3.5  and the crystal structure of Atlantic salmon trypsin (pdb code: 1hj8) as a structural template. The homology model of king crab trypsin, the structures of Atlantic salmon trypsin (pdb code: 1hj8) and bovine trypsin (pdb code: 1s0r) were superimposed on the thrombin-PAR-4 structure (pdb code: 2pv9; ). The backbone of the catalytic site residues in the trypsins were superimposed with the corresponding residues of the PAR-4-thrombin complex. A model of the N-terminal fragment of human PAR-2 (Gly28-Val53) was build and superimposed on top of the corresponding PAR-4 segment in the crystal structure of the thrombin-PAR-4 complex. Electrostatic potentials were calculated on the molecular surfaces of the model and structures of the trypsins.
Effect of temperature on enzymatic activity
Molecular modelling shows differences in the protein structure of the king crab trypsin compared to salmon and bovine trypsin
Comparison of the homology model of king crab trypsin with the structures of Atlantic salmon and bovine trypsin suggested that at least 3 divergent positions are located near the substrate binding pocket (Figure 3d): Asp196 in king crab trypsin corresponds to Met175 in the Atlantic salmon trypsin structure and to Gln155 in the bovine trypsin structure; Arg244 in king crab trypsin corresponds to Glu221 in Atlantic salmon trypsin and to Gln199 in bovine trypsin; while Tyr247 in king crab trypsin corresponds to Asn224 in salmon trypsin and to Lys202 in bovine trypsin.
A recent study by Ramachandran and co-workers  reports the ability of PAR-2 to exhibit functional selectivity where the proteolytically revealed tethered ligand (TL) sequence(s) and the mode of its presentation to the receptor (tethered vs. soluble) can confer biased signalling. Thus, PAR-2 can signal to multiple pathways that are differentially triggered by distinct protease-revealed tethered ligands. Differential signalling depending on the activating ligand (termed “agonist-biased signalling” or “functional selectivity”) are also reported for other G protein-coupled receptors [29–32]. The exact factors that lead to activation of different signal pathways during binding of agonist to and cleavage of PAR-2 are unknown. Molecular modelling of the human PAR-1 has revealed various electrostatic, steric, and hydrophobic interactions between receptor and the antagonist used in docking studies . Some residues identified as main points for electrostatic interactions have previously been reported as important in site directed mutagenesis studies for PAR-1 function and activity (Asp256 and Glu347) . It is tempting to speculate that functional selectivity is a result of different capacity in the agonists to bind at these various interaction points.
Furthermore, the positive Arg5 in the agonist peptide is from receptor chimera studies in PAR-1 suggested to interact with the negative Glu260 in the second extracellular loop of PAR-1 during receptor activation [35, 36]. Since these amino acids are conserved in PAR-2 an Arg5-Glu232 interaction might operate in recognition of the PAR-2 agonist peptide SLIGRL by the receptor. Changing this residue in the PAR-2 agonist peptide (the positive Arg5 in SLIGR L to a neutral alanine or a negative glutamatic acid creating SLIGA L or SLIGE L) markedly reduces the peptides’ potency to cause intracellular Ca2+ signalling . The Al-Ani study  indicate that changes in the net charge of interacting amino acids influence on activating capacity; a result that may be due to interference with electrostatic interactions.
Differences in IL-8 secreting potential and NF-κB activation have been identified for salmon and king crab trypsin. Both effects are coupled to PAR-2 activation, but only partly for the king crab trypsin [6, 16]. Molecular modelling shows that the surface of king crab trypsin has a large area with strong negative electrostatic potential compared to the smaller areas of bovine and salmon trypsins. In addition, these latter trypsins also display areas with strong positive electrostatic potential, a feature lacking in king crab trypsin. Because of the lack of a full amino acid sequence of the sardine trypsin molecule we were not able to do any modelling of and comparison with sardine trypsin.
The negative Asp196 in king crab trypsin corresponds to the neutral Met175 in salmon trypsin and the neutral Gln155 in bovine trypsin.
The positive Arg244 in the king crab trypsin corresponds to the negative Glu221 in salmon trypsin and the neutral Gln199 in bovine trypsin.
The neutral Tyr247 in king crab trypsin corresponds to the neutral Asn224 in salmon trypsin and to the positive Lys202 in bovine trypsin.
It is possible that the positive Arg36 and/or positive Lys34 of PAR-2 may interact differently with the binding pocket in the three trypsins. Because of differences in the electrostatic potential it is possible that PAR-2 might bind weaker to king crab trypsin than to other trypsins due to repulsive interactions between the positive Lys34/ Arg36 in PAR-2 and the positively charged Arg244 in king crab trypsin. This residue corresponds to a negative amino acid (Glu221) in salmon trypsin and a neutral amino acid (Gln199) in bovine trypsin. Zhang and co-workers  have recently documented that long-range electrostatic interactions presumably play an important role in aligning the PAR-2 N-terminal polypeptide with the activating protease (factor VIIa (FVIIa)) domain during binding and subsequent activation of PAR-2. By molecular simulations they show that positive amino acids in the proximity of the cleavage site of PAR-2 (Arg31, Lys34, and Arg36) are located close to negatively charged residues on the binding pocket surface of FVIIa, whereas the negatively charged Asp43 and Glu56 are close to positively charged FVIIa residues. Although cell-based control studies were not conclusive (antibodies blocking possible PAR-2 interacting residues in the FVIIa molecule resulted in inhibited tissue factor (TF)-FVIIa signalling through PAR-2, while charge reversal mutations in FVIIa (positive Arg62 to negative Glu62, and positive Arg84 to negative Glu84) did not significantly inhibit PAR-2 activation), we can not eliminate the possibility that electrostatic interactions in specific regions guide substrate orientation under physiological conditions. However, the specific FVIIa Arg62 – PAR-2 Glu56 interaction seems not to be essential for PAR-2 activation by TF-FVIIa.
The measurement of enzymatic activity at different concentrations both at room temperature and 37°C using DL-BAPNA as substrate yielded two separate but similar patterns among the four types of trypsins tested, with bovine and king crab trypsin in the lower area and the fish trypsins in the higher area. During the purification process the bovine trypsin behaved like the fish trypsins with regards to the binding capacity, giving rise to an inconsistency as it had similar enzymatic activity as the king crab trypsin. On the other hand, binding of trypsins to the N-terminal end of PAR-2 for cleavage and subsequent receptor activation might behave different from the binding and cleavage of the substrate in the serine protease assay, giving rise to differences in agonist potential in cell based assays.
These preliminary results indicate that electrostatic interactions can be of importance in binding, cleavage and subsequent activation of PAR-2, and that difference in electrostatic charge in residues at key interacting positions may result in altered potency of the agonist in question. However, more extensive molecular modelling of the entire PAR-2 together with docking studies of different agonists and functional binding assays (Isothermal Titration Calorimetry, Fluorescence Resonance Energy Transfer) to independently quantify the binding capacity of all the trypsins to PAR-2 peptide would be highly interesting. Mutations of key amino acids or generation of chimeric trypsins to investigate the structure and activity relationship, along with cell based assays, are necessary to identify essential residues that might influence upon functional selectivity.
The results indicate that electrostatic interactions could be of importance in binding, cleavage and subsequent activation of PAR-2 and differences in electrostatic charge in residues at key interacting positions may result in altered potency of the agonists in questions.
Availability of supporting data
The models constructed in this study are available from the authors upon request.
We thank the personnel at NORSTRUCT, University of Tromsø for excellent technical assistance during purification of the trypsins. This work was supported by Northern Norway Regional Health Authority (Helse Nord RHF), 8038 Bodø, Norway.
- Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J: Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem. 1995, 232: 84-89. 10.1111/j.1432-1033.1995.tb20784.x.PubMedView Article
- Böhm SK, Kong W, Brömme D, Smeekens SP, Anderson DC, Connolly A, Kahn M, Nelken NA, Coughlin SP, Payan DG, Bunnett NW: Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996, 314: 1009-1016.PubMedPubMed CentralView Article
- Ossovskaya VS, Bunnett NW: Protease-activated receptors: Contribution to physiology and disease. Physiol Rev. 2004, 84: 579-621. 10.1152/physrev.00028.2003.PubMedView Article
- Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD: A protective role for protease-activated receptors in the airways. Nature. 1999, 398: 156-160. 10.1038/18223.PubMedView Article
- Ramachandran R, Hollenberg MD: Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol. 2008, 153 (Suppl 1): S263-S282.PubMedPubMed Central
- Larsen AK, Seternes OM, Larsen M, Aasmoe L, Bang B: Salmon trypsin stimulates the expression of interleukin-8 via protease-activated receptor-2. Toxicol Appl Pharmacol. 2008, 230: 276-282. 10.1016/j.taap.2008.02.019.PubMedView Article
- Orford RR, Wilson JT: Epidemiologic and immunologic studies in processors of the king Crab. Am J Ind Med. 1985, 7: 155-169. 10.1002/ajim.4700070207.PubMedView Article
- Cartier A, Malo JL, Ghezzo H, McCants M, Lehrer SB: IgE sensitization in snow crab-processing workers. J Allergy Clin Immunol. 1986, 78: 344-348. 10.1016/S0091-6749(86)80087-2.PubMedView Article
- Jeebhay MF, Robins TG, Lehrer SB, Lopata AL: Occupational seafood allergy: a review. Occup Environ Med. 2001, 58: 553-562. 10.1136/oem.58.9.553.PubMedPubMed CentralView Article
- Jeebhay MF, Robins TG, Miller ME, Bateman E, Smuts M, Baatjies R, Lopata AL: Occupational allergy and asthma among salt water fish processing workers. Am J Ind Med. 2008, 51: 899-910. 10.1002/ajim.20635.PubMedPubMed CentralView Article
- Ortega HG, Daroowalla F, Petsonk EL, Lewis D, Berardinelli S, Jones W, Kreiss K, Weissman DN: Respiratory symptoms among crab processing workers in Alaska: Epidemiological and environmental assessment. Am J Ind Med. 2001, 39: 598-607. 10.1002/ajim.1059.PubMedView Article
- Bang B, Aasmoe L, Aamodt BH, Aardal L, Andorsen GS, Bolle R, Bøe R, Van Do T, Evans R, Florvåg E, Gram IT, Huser PO, Kramvik E, Løchen ML, Pedersen B, Rasmussen T: Exposure and airway effects of seafood industry workers in Northern Norway. J Occup Environ Med. 2005, 47: 482-492. 10.1097/01.jom.0000161732.96555.2b.PubMedView Article
- Howse D, Gautrin D, Neis B, Cartier A, Horth-Susin L, Jong M, Swanson MC: Gender and snow crab occupational asthma in Newfoundland and Labrador, Canada. Environ Res. 2006, 101: 163-174. 10.1016/j.envres.2005.06.008.PubMedView Article
- Gautrin D, Cartier A, Howse D, Horth-Susin L, Jong M, Swanson M, Lehrer S, Fox G, Neis B: Occupational asthma and allergy in snow crab processing in Newfoundland and Labrador. Occup Environ Med. 2010, 67: 17-23. 10.1136/oem.2008.039578.PubMedView Article
- Shiryaeva O, Aasmoe L, Straume B, Bang BE: Respiratory impairment in Norwegian salmon industry workers: a cross-sectional study. J Occup Environ Med. 2010, 52: 1167-1172. 10.1097/JOM.0b013e3181fc5e35.PubMedView Article
- Larsen AK, Seternes OM, Larsen M, Kishimura H, Rudenskaya GN, Bang B: Purified sardine and king crab trypsin display individual differences in PAR-2-, NF-κB-, and IL-8 signaling. Toxicol Environ Chem. 2011, 93: 1991-2011. 10.1080/02772248.2011.614380.View Article
- Kangas E, Tidor B: Optimizing electrostatic affinity in ligand-receptor binding: Theory, computation, and ligand properties. J Chem Phys. 1998, 109: 7522-7545. 10.1063/1.477375.View Article
- Green DF, Tidor B: Evaluation of electrostatic interactions. Curr Protoc Bioinformatics. 2003, 10.1002/0471250953.bi0803s02. Aug; Chapter 8:Unit 8.3
- Rang HP, Dale MM, Ritter JM: How drugs act: general principles and molecular aspects. Pharmacology. Edited by: Hunter L. 1999, Edinburgh: Churchill Livingstone, Harcourt Brace and Company Ltd, 2-45. 4
- Rudenskaya GN, Isaev VA, Shmoylov AM, Karabasova MA, Shvets SV, Miroshnikov AI, Brusov AB: Preparation of proteolytic enzymes from Kamchatka crab Paralithodes camchatica hepatopancreas and their application. Appl Biochem and Biotech. 2000, 88: 175-183. 10.1385/ABAB:88:1-3:175.View Article
- Kislitsyn YA, Rebrikov DV, Dunaevskii YA, Rudenskaya GN: Isolation and primary structure of trypsin from the King crab Paralithodes camchaticus. Russian J of Bioorg Chem. 2003, 29: 242-248. 10.1023/A:1023932415680.View Article
- Kishimura H, Hayashi K, Miyashita Y, Nonami Y: Characteristics of trypsins from the vicera of true sardine (Sardinops melanostictus) and the pyloric ceca of arabesque greenling (Pleuroprammus azonus). Food Chem. 2006, 97: 65-70. 10.1016/j.foodchem.2005.03.008.View Article
- Outzen H, Berglund GI, Smalås AO, Willassen NP: Temperature and pH sensitivity of trypsins from Atlantic Salmon (Salmo salar) in comparison with bovine and porcine trypsin. Comp Biochem Physiol B Biochem Mol Biol. 1996, 115: 33-45. 10.1016/0305-0491(96)00081-8.PubMedView Article
- Erlanger BF, Kokowsky N, Cohen W: The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys. 1961, 95: 271-278. 10.1016/0003-9861(61)90145-X.PubMedView Article
- Abagyan R, Totrov M: Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol. 1994, 235: 983-1002. 10.1006/jmbi.1994.1052.PubMedView Article
- Bah A, Chen Z, Bush-Pelc LA, Mathews FS, Di Cera E: Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci USA. 2007, 104: 11603-11608. 10.1073/pnas.0704409104.PubMedPubMed CentralView Article
- Smalås AO, Hordvik A, Hansen LK, Hough E, Jynge K: Crystallization and preliminary X-ray crystallographic studies of benzamidine-inhibited trypsin from the North Atlantic salmon (Salmo Salar). J Mol Biol. 1990, 214: 355-358. 10.1016/0022-2836(90)90185-O.PubMedView Article
- Ramachandran R, Mihara K, Mathur M, Rochdi MD, Bouvier M, DeFea K, Hollenberg MD: Agonist-biased signalling via proteinase activated receptor-2: differential activation of calcium and MAPkinase pathways. Mol Pharmacol. 2009, 76: 791-801. 10.1124/mol.109.055509.PubMedPubMed CentralView Article
- Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ: Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA. 2003, 100: 10782-10787. 10.1073/pnas.1834556100.PubMedPubMed CentralView Article
- Galandrin S, Oligny-Longpré G, Bouvier M: The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci. 2007, 28: 423-430. 10.1016/j.tips.2007.06.005.PubMedView Article
- Kenakin T: Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci. 2007, 28: 407-415. 10.1016/j.tips.2007.06.009.PubMedView Article
- Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB: Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007, 320: 1-13.PubMedView Article
- Saxena AK, Alam I, Dixit A, Saxena M: Internet resources in GPCR modelling. SAR QSAR Environ Res. 2008, 19: 11-25. 10.1080/10629360701844126.PubMedView Article
- Blackhart BD, Ruslim-Litrus L, Lu CC, Alves VL, Teng W, Scarborough RM, Reynolds EE, Oksenberg D: Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol Pharmacol. 2000, 58: 1178-1187.PubMed
- Gerszten RE, Chen J, Ishii M, Ishii K, Wang L, Nanevicz T, Turck CW, Vu TK, Coughlin SR: Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994, 368: 648-651. 10.1038/368648a0.PubMedView Article
- Nanevicz T, Ishii M, Wang L, Chen M, Chen J, Turck CW, Cohen FE, Coughlin SR: Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J Biol Chem. 1995, 270: 21619-21625. 10.1074/jbc.270.37.21619.PubMedView Article
- Al-Ani B, Wijesuriya SJ, Hollenberg MD: Proteinase-activated receptor 2: differential activation of the receptor by tethered ligand and soluble peptide analogs. J Pharmacol Exp Ther. 2002, 302: 1046-1054. 10.1124/jpet.302.3.1046.PubMedView Article
- Zhang Q, Petersen HH, Ostergaard H, Ruf W, Olson AJ: Molecular dynamics simulations and functional characterization of the interactions of the PAR2 ectodomain with factor VIIa. Proteins. 2009, 77: 559-569. 10.1002/prot.22468.PubMedPubMed CentralView Article